PROVIDER STATEMENT

Provided by Integrity Continuing Education, Inc. and Tumor Board Tuesday.

MODERATOR

Michael J. Pishvaian, MD, PhD Associate Professor, Department of Oncology Director of the Gastrointestinal, Development Therapeutics, and Clinical Research Programs at the NCR Kimmel Cancer Center at Sibley Memorial Hospital Johns Hopkins University School of Medicine Washington, District of Columbia

SCHEDULE

#TumorBoardTuesday takes place on Tuesdays at 8 PM Eastern Time. You can join the conversation at https://twitter.com/TumorBoardTues [table id=71 /]

PROGRAM OVERVIEW

Oncologists and other clinicians who treat patients with gastrointestinal (GI) cancers have generally adopted molecular profiling technologies offering insight into the molecular underpinning of colorectal, gastric, esophageal, and biliary tumors. Considering the challenges of managing these tumor types, understanding these molecular alterations is critical to incorporating newly approved and emerging targeted agents, including immunotherapies. Yet, translating these findings into clinical applications can be challenging. Determining which potential biomarkers and/or druggable mutations in GI cancers that benefit patients is instrumental in improving patient outcomes. Oncologists need greater understanding and insight into the foundational genomic discoveries that underlie the use of targeted entities.

Tumor Board Tuesdays is a bi-weekly, Twitter-based case discussion forum led by expert faculty exploring cases in various solid tumor malignancies. The series will focus on practice application in the clinic. Experts will present recent data and focus on realistic case examples. The advantage to this format is the ability to comment and receive feedback from the experts.

TARGET AUDIENCE

This activity is designed to meet the needs of medical oncologists, physicians assistants, nurse practitioners, interventional radiologists, surgeons, pathologists and other HCPs involved in the treatment and management of patients with solid tumors.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants will be able to:

Elucidate the genomic, immunogenic, and proteomic aberrations that serve as molecular drivers for a wide variety of solid tumors and mandate the necessity for a personalized approach to treatment
Select personalized treatments for patients with breast, gastrointestinal, genitourinary, and lung cancer based on the characteristics of each patient and the molecular profile of each tumor
Assess treatments currently in late-phase development that are being studied for their ability to address actionable molecular targets common to disease state subsets within breast, gastrointestinal, genitourinary, and lung cancers

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the certification period, participants must:

Read the learning objectives and faculty disclosures
Complete the pretest
Study the educational activity
Complete the posttest and the evaluation form

If you wish to claim credit for your participation in TBT conversations from April 12, 2022 - Present you can do so here: www.integrityce.com/TBTEval

MEDIA

Internet

ACCREDITATION

Physician Continuing Education

Accreditation Statement This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Integrity Continuing Education, Inc. and Tumor Board Tuesday. Integrity Continuing Education, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this live material for a maximum of 34.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 31.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The faculty/planners listed in the schedule portion of this page reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities.

Michael L. Pishvaian, MD, PhD Ad Hoc Advisory Boards: AstraZeneca, Foundation Medicine, Merck Educational (Unbranded) Program Speaker: Novartis, Pfizer Funding to Institution: Arcus, Merck, Seattle Genetics Stock Ownership: Perthera, Inc. The Integrity Continuing Education, Inc. and Tumor Board Tuesday planners/managers do not have any conflicts of interest to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent) Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS Plug-in: Adobe^® Flash^® Player 10

Adobe^® Flash^® Player 10 plug-in should be downloaded
Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended. For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below Click here for more information on minimum system requirements.

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

DISCLOSURE OF COMMERCIAL SUPPORT

Supported by educational grants from AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc.; Exelixis, Inc.; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; Merck Sharp & Dohme Corp.; Regeneron Pharmaceuticals, Inc. and Sanofi.

@TumorBoardTues Case Conversations_2022